IBBME Special Lecture: Emil Schemitsch
August 12 @ 11:00 am - 12:00 pm
Click on the image above to view a full-size version of this event’s poster in your browser.
The use of bone substitutes in fracture repair in 2014 and beyond!
The repair of large bone defects caused by trauma and the treatment of non or delayed-union continues to be a major clinical challenge in orthopaedics. In Canada, trauma is the leading cause of death in people younger than 45, and musculoskeletal injuries account for 79% of all major injury hospitalizations. Tibial shaft fractures are the most commonly occurring long bone fractures and are often complicated by delayed or non-union. Estimates of these complication rates range from 4% to 48%, often resulting in the need for additional treatments and re-operations.
Autologous bone grafting remains the gold standard of treatment for the repair of these large bone defects, but this technique has numerous limitations, including morbidity and post-operative pain at the harvest site, limited volumes of graft material, and neurovascular injury, infection and other complications. Allografts provide structural integrity but are limited by issues such as disease transmission and availability. Other techniques, including calcium sulphates, calcium phosphates and BMPs, have additional limitations.
To address these shortcomings, many investigators have proposed cell-based therapies for the healing of bone. Our central premise is that Endothelial Progenitor Cell-based therapy will result in improved union rates of bone defects. This could have significant clinical implications for treatment of segmental defects and delayed or non-union in humans.
Dr. Emil Schemitsch, Professor of Surgery at the University of Toronto, is past head of the Division of Orthopaedic Surgery at St. Michael’s Hospital at the University of Toronto. Dr. Schemitsch is a Scientist at the Keenan Research Centre of the Li Ka Shing Knowledge Institute at St. Michael’s Hospital. A University of Toronto graduate in Medicine, Dr. Schemitsch completed his orthopaedic training at the University of Toronto. To broaden his clinical exposure, he trained at the University of Washington (Harborview Medical Center) and Harvard University. Dr. Schemitsch’s clinical interests include the management of patients with complex upper and lower extremity fractures, hip and knee reconstruction and computer assisted surgery.
Dr. Schemitsch’s research has focused upon the care of patients with musculoskeletal injuries. His basic research interests include the systemic response to trauma, gene therapy, biomechanics, bone substitutes and the stimulation of fracture healing. His clinical research interests include computer assisted surgery, clinical trials and outcomes studies in upper and lower extremity trauma. He has received international recognition for his research efforts and is Past-President of the Canadian Orthopaedic Association.
Dr. Schemitsch’s program of research in musculoskeletal trauma and arthritis has led to more than 375 publications in top journals, numerous grants (CIHR, PSI, OTA) and hundreds of guest lectures around the world.